- Total
- General
- Arts
- Book
- Culture
- Economy
- Essay
- Fun/Joke
- History
- Hobbies
- Info
- Life
- Medical
- Movie
- Music
- Nature
- News
- Notice
- Opinion
- Philosophy
- Photo
- Poem
- Politics
- Science
- Sports
- Travel
General An Effective Anti COVID19 Drug by Eli Lilly
2020.09.16 07:38
An experimental drug is showing promise in reducing blood levels of the virus for newly infected patients.(NYTimes reports 9/16/20)
A single infusion of an experimental drug has markedly reduced blood levels of the coronavirus in newly infected patients and lowered the chances that they will need hospitalization, the drug’s maker announced on Wednesday.
The drug is a monoclonal antibody, a man-made copy of an antibody produced by a patient who recovered from Covid-19, the illness caused by the coronavirus. Many scientists hope that monoclonal antibodies will prove to be powerful treatments for Covid-19, but they are difficult to manufacture and progress has been slow.
The announcement, by Eli Lilly, was not accompanied by detailed data; independent scientists have not yet reviewed the results, nor have they been published in a peer-reviewed journal.
The findings are the interim results of a trial sponsored by Eli Lilly and the National Institutes of Health. Officials at the N.I.H. declined to comment until they have more thoroughly reviewed the data.
According to Eli Lilly, 452 newly diagnosed patients received the monoclonal antibody or a placebo infusion. Some 1.7 percent of those who got the drug were hospitalized, compared with 6 percent of those who received a placebo — a 72 percent reduction in risk.
Blood levels of the coronavirus plummeted among participants who received the drug, and their symptoms were fewer, compared with those who got the placebo.
Every treatment so far shown to help coronavirus patients — the antiviral drug remdesivir and the steroid dexamethasone — is intended only for seriously ill hospitalized patients. Those with mild to moderate disease have had to wait and hope for the best.
Dr. Myron Cohen, director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said he was impressed.
“It’s exciting,” said Dr. Cohen, who was not involved in the study. The clinical trial appears to be rigorous, and the results are “really compelling.”
Other companies, too, are developing monoclonal antibody drugs to combat the coronavirus, he noted: “This is the opening of a door.”
| No. | Subject | Date | Author | Last Update | Views |
|---|---|---|---|---|---|
| Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18162 |
| Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32304 |
| Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5890 |
| Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43807 |
| 8822 | AMAZING GRACE [1] | 2024.03.01 | 정관호*63 | 2024.03.08 | 65 |
| 8821 | 한국에의 복수국적 - 이중국적이 더 불리한 경우를 알려 드립니다 [1] | 2024.02.24 | 운영자 | 2024.02.24 | 82 |
| 8820 | 신진서, 농심배 16연승... 중국 기사 올킬로 한국 4연속 우승 [1] | 2024.02.23 | 황규정*65 | 2024.02.23 | 47 |
| 8819 | 古朝鮮:고조선 [1] | 2024.02.23 | 정관호*63 | 2024.02.26 | 52 |
| 8818 | 한국진공작전; Eagle Project and Napko Project [2] | 2024.02.22 | 온기철*71 | 2024.02.28 | 90 |
| 8817 | 일제의 김구 암살 공작과 밀정 [2] | 2024.02.19 | 온기철*71 | 2024.02.22 | 79 |
| 8816 | 장개석은 한국에 친중정부가 수립 되게 하려고 임정을 도왔다. [1] | 2024.02.17 | 온기철*71 | 2024.02.24 | 89 |
| 8815 | 봄날의 원망 [1] | 2024.02.16 | 정관호*63 | 2024.02.16 | 46 |
| 8814 | 내 마음은 가을 달 [1] | 2024.02.08 | 정관호*63 | 2024.02.14 | 482 |
| 8813 | 1945년8월15일은 과연 해방이었을까? [2] | 2024.02.06 | 온기철*71 | 2024.02.07 | 68 |
| 8812 | Pearl Buck 과 유일한 [2] | 2024.02.02 | 온기철*71 | 2024.02.05 | 87 |
| 8811 | 연꽃 한송이 [1] | 2024.02.01 | 정관호*63 | 2024.02.01 | 56 |
| 8810 | 1947 년 Wedemeyer 사절단 방한과 미국의 대한정책 [1] | 2024.01.28 | 온기철*71 | 2024.02.02 | 57 |
| 8809 | 東北工程: 동북공정 [7] | 2024.01.23 | 정관호*63 | 2024.02.06 | 276 |
| 8808 | 리디아 고, LPGA 개막전서 통산 20승...명예의 전당 눈앞 [2] | 2024.01.22 | 황규정*65 | 2024.01.22 | 118 |
| 8807 | ‘이강인 멀티골’ 한국, 바레인 3-1 제압…아시안컵 산뜻한 출발 [16] | 2024.01.15 | 황규정*65 | 2024.02.07 | 79 |
| 8806 | 詠懷古蹟 其五(영회고적 기오) :고적에서 회포를 읊다 5회 제갈랑 편 [1] | 2024.01.15 | 정관호*63 | 2024.01.17 | 57 |
| 8805 | 해방정국 정치세력 [1] | 2024.01.10 | 온기철*71 | 2024.01.12 | 69 |
| 8804 | 詠懷古蹟 其四(영회고적 4회): 고적에서 회포를 읊다. 4회. 유비 편 [1] | 2024.01.07 | 정관호*63 | 2024.03.04 | 82 |
| 8803 |
Happy New Year!
[4]  | 2023.12.31 | 조승자#65. | 2024.01.16 | 146 |
Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment
An experimental COVID-19 treatment hit the mark in an 800-patient clinical trial.
Cory Renauer
(TMFang4apples)
Sep 16, 2020 at 2:11PM
Author Bio
Get ready for the best coronavirus news we've seen from the biopharmaceutical industry to date. An interim peek at a clinical trial with an experimental treatment from Eli Lilly (NYSE:LLY) suggests LY-CoV555 could be an effective treatment option for COVID-19 patients with mild-to-moderate symptoms.
The first experimental COVID-19 antiviral treatment to score
The FDA has granted, and in some cases rescinded, emergency use authorizations for COVID-19 treatments that were around before SARS-CoV-2 made its debut in late 2019. If authorized, Lilly could launch the first treatment aimed directly at the novel coronavirus responsible for the pandemic. Back in March, Eli Lilly and its collaboration partner, AbCellera, isolated a pair of promising antibodies, LY-CoV555 and LY-CoV016, from a panel of more than 500 proteins found in blood samples of COVID-19 patients who recovered.
IMAGE SOURCE: GETTY IMAGES.
In June, Eli Lilly and AbCellera began the Blaze-1 study, a controlled, randomized trial currently testing LY-CoV555, and a combination of LY-CoV555 and LY-CoV016 as potential treatments for patients with mild-to-moderate COVID-19 symptoms. The primary outcome being measured is the difference in viral load 11 days after beginning treatment, and it looks like one of three dosages of LY-CoV555 tested as a monotherapy hit the mark.
At the interim analysis, the 2,800-milligram dosage significantly reduced the amount of circulating SARS-COV-2, but the differences observed with the 700-milligram dosage and the 7,000-milligram dosage didn't reach statistical significance on day 11.
It's important to hit the goals set out at the beginning of a clinical trial, but outcome measurements are what matters most. An ongoing phase 3 trial with LY-CoV555 will provide a clearer picture, but it looks like this treatment will become a powerful weapon for healthcare providers fighting the COVID-19 pandemic. COVID-19-positive patients treated with any dosage strength were 77% less likely to report a COVID-19-relatedhospitalization or ER visit.